NRx Pharmaceuticals (Nasdaq:NRXP) announces elimination of all balance sheet debt following equity conversion
NRX Pharmaceuticals, Inc. (NRXP)
Company Research
Source: GlobeNewswire
Remaining $5.4 million debt was repaid through strategic equity conversion in common stock with no additional warrants or adjustment provisionsCompany anticipates that Dec 31 balance sheet will reflect no outstanding convertible debtDebt-free balance sheet sets the stage for accelerated growth in 2026 with potential drug approvals and clinic expansions WILMINGTON, Del., Dec. 18, 2025 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), a clinical-stage biopharmaceutical company, today announced that it has repaid the remaining $5.4 million balance sheet debt to Anson Funds, LLC, through equity conversion of common stock. There were no warrants or other repricing mechanisms associated with this transaction. Anson originally lent $16.2 million USD to the Company to fund repayment of prior loans and corporate operating expenses. With this repayment, the Company anticipates ending the 2025 calendar year with a balance sheet free of all debt. NRx believes that this milestone pr
Show less
Read more
Impact Snapshot
Event Time:
NRXP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NRXP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NRXP alerts
High impacting NRX Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
NRXP
News
- NRx Pharmaceuticals (NASDAQ:NRXP) had its "sell (e+)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- NRx Pharmaceuticals (Nasdaq:NRXP) announces elimination of all balance sheet debt following equity conversion [Yahoo! Finance]Yahoo! Finance
- NRx Pharmaceuticals (NASDAQ:NRXP) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $40.00 price target on the stock.MarketBeat
- NRx Pharmaceuticals (NASDAQ:NRXP) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $25.00 price target on the stock.MarketBeat
- NRx Pharmaceuticals to discuss new NRX-101 pipeline indication for augmentation of Transcranial Magnetic StimulationGlobeNewswire
NRXP
Earnings
- 11/14/25 - Miss
NRXP
Sec Filings
- 12/12/25 - Form S-3/A
- 11/26/25 - Form 8-K
- 11/21/25 - Form 8-K/A
- NRXP's page on the SEC website